We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Reasons for Rejecting Blood Samples Analyzed

By LabMedica International staff writers
Posted on 24 Jan 2012
Print article
A determination has been made of what types of preanalytical errors that leads to rejection of blood samples in the clinical laboratory.

Errors in clinical laboratories have a great impact on safety and care of patients, and need to be carefully analyzed for improvements to be made in the preanalytical phase, which is responsible for about 70% of errors.

Laboratory scientists at the University Hospital (Porto Alegre, Brazil) carried out an analysis of rejected samples and consequent request for new daily collections of blood for conduction of tests in the following analytical departments: biochemical-immunoassay and hematology. The analysis was performed on data collected from June to August 2010.

The rejection criteria in clotted, hemolyzed, icteric and lipemic samples were visually applied by two technologists and the criterion for the clotted sample was only analyzed in samples collected in ethylenediamine tetra-acetic acid (EDTA) or sodium citrate tubes. The rejection criterion for icteric samples was applied in samples with seric bilirubin levels greater than 25 mg/L that could interfere with the measurement of some tests, such as those for albumin, cholesterol, and total protein. Lipemic samples, in turn, were rejected when serum triglycerides levels exceeded 400 mg/dL, as that may inhibit the tests for amylase, uric acid, urea, bilirubin and total protein.

Of the 77,051 blood samples that were collected during the three months period, 441 (0.57%) were rejected by some type of preanalytical error and therefore had to be recollected. A clot was found in 43.8% of disallowed samples and was found to be the major cause of rejection of samples, followed by 24% with insufficient sample volume. The third most frequent cause for rejecting samples were hemolyzed samples, which involved 17.9% of cases. Other reasons for rejection of samples were misidentification, inappropriate tube, lipemic samples, inadequate sample/additive ratio, and insignificant icteric samples.

The authors concluded that in their laboratory, despite the percentage of preanalytical errors being small, the appearance of laboratory errors could be provoke an adverse impact on patient care. For example, when blood constituents such as potassium, magnesium, iron, lactate dehydrogenase, phosphorus, ammonium, and total protein are falsely increased during hemolysis. In this context, the poor quality specimens could influence laboratory results, which would be clinically incorrect and therefore mislead the physician whose intervention might be unsuccessful. The study was published in January 2012 in the journal Clinical Biochemistry.

Related Links:

University Hospital Porto Alegre


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.